GO:0001570 vasculogenesis: De Novo Blood Vessel Formation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001570 vasculogenesis is defined as the differentiation of endothelial cells from progenitor cells during blood vessel development, and the de novo formation of blood vessels and tubes.
• Vasculogenesis is distinct from angiogenesis: it creates the first primitive vascular plexus from endothelial progenitors, whereas angiogenesis remodels and expands existing vessels.
• The process is driven by hemangioblasts and angioblasts, which differentiate into endothelial cells and assemble into cord-like structures that lumenize into tubes.
• Vasculogenesis is not restricted to embryogenesis; postnatal vasculogenesis contributes to tumor vascularization, infantile hemangioma, and tissue repair.
• Key molecular players include VEGFA, VEGFR2 (KDR), CDH5 (VE-cadherin), TIE2 (TEK), and the transcription factor ETV2, which are essential for endothelial specification and tube formation.
• Dysregulated vasculogenesis is implicated in clear cell renal cell carcinoma, infantile hemangioma, and cardiovascular disease, making it a target for therapeutic and biomarker research.
Description
Vasculogenesis (GO:0001570) is the biological process by which endothelial cells differentiate from progenitor cells and assemble into the first de novo blood vessels and tubes during development. This process is fundamental to the establishment of the embryonic circulatory system and is distinct from angiogenesis, which refers to the sprouting and remodeling of pre-existing vessels. The term encompasses the specification of hemangioblasts and angioblasts, their differentiation into endothelial cells, and the morphogenetic events that generate a primitive vascular plexus. Understanding vasculogenesis is critical because it provides the architectural blueprint for all subsequent vascular development and has been shown to persist postnatally in specific physiological and pathological contexts. In recent years, vasculogenesis has gained attention beyond developmental biology, as it contributes to tumor vascularization, regenerative medicine, and tissue engineering. For researchers, GO:0001570 represents a convergence point for stem cell biology, vascular biology, and disease modeling, offering opportunities to interrogate endothelial lineage commitment and tube morphogenesis using CRISPR-based approaches.
vasculogenesis At A Glance
| GO ID | GO:0001570 |
|---|---|
| GO term | vasculogenesis |
| Ontology | biological_process |
| Synonym | vascular morphogenesis |
| Definition | The differentiation of endothelial cells from progenitor cells during blood vessel development, and the de novo formation of blood vessels and tubes. |
| Major function | De novo formation of blood vessels and tubes from endothelial progenitors. |
| Key cell types | Hemangioblasts, angioblasts, endothelial cells. |
| Related process | Angiogenesis (sprouting from existing vessels). |
| Postnatal relevance | Contributes to tumor vascularization, hemangioma, and tissue repair. |
What Is GO:0001570?
According to the Gene Ontology, GO:0001570 vasculogenesis is defined as the differentiation of endothelial cells from progenitor cells during blood vessel development, and the de novo formation of blood vessels and tubes. In other words, it is the process that creates new blood vessels from scratch, starting with progenitor cells such as hemangioblasts and angioblasts, rather than by sprouting from existing vessels. This definition distinguishes vasculogenesis from angiogenesis, which involves the growth of new capillaries from pre-existing vascular networks. The term is synonymous with vascular morphogenesis and is classified as a biological process in the GO ontology.
Why Is vasculogenesis Important in Cell Biology?
Vasculogenesis is important because it establishes the primary vascular network during embryogenesis and contributes to postnatal vascularization in both health and disease. Defects in this process can lead to embryonic lethality, cardiovascular malformations, and impaired tissue repair. Moreover, the reactivation of vasculogenesis in adults is a hallmark of tumor progression, where it supports the growth of clear cell renal cell carcinoma and other malignancies. Understanding the molecular and cellular mechanisms of vasculogenesis is therefore essential for developing targeted therapies, improving regenerative medicine strategies, and creating accurate disease models.
• Vasculogenesis is the earliest step in blood vessel formation, establishing the primitive vascular plexus during embryogenesis.
• It is distinct from angiogenesis and is required for the development of the heart and major vessels.
• Postnatal vasculogenesis contributes to tumor vascularization and is a target for anti-angiogenic therapy.
• Infantile hemangioma, a common benign vascular tumor, involves vasculogenesis-like processes.
• Vasculogenesis is critical for tissue engineering and 3D bioprinting of vascularized constructs.
• Dysregulation of vasculogenesis is linked to clear cell renal cell carcinoma progression and therapy response.
• Endothelial progenitor cells derived from vasculogenesis are being explored for cell therapy.
• Studying vasculogenesis provides insights into stem cell differentiation and lineage commitment.
• It serves as a model for understanding tube morphogenesis and lumen formation.
• Genetic and epigenetic regulation of vasculogenesis informs precision medicine approaches.
What Happens During vasculogenesis?
Specification of Hemangioblasts and Angioblasts
In simple terms: First, special progenitor cells are told to become blood vessel cells.
Vasculogenesis begins with the specification of hemangioblasts, bipotent progenitors that can give rise to both hematopoietic and endothelial lineages. These cells arise from the mesoderm and are characterized by the expression of markers such as VEGFR2 (KDR) and TAL1. The search for the hemangioblast has been a central theme in vascular biology, with evidence from embryonic stem cell differentiation and zebrafish models. Following specification, hemangioblasts differentiate into angioblasts, which are committed endothelial progenitors. This step is regulated by signaling pathways including VEGF, Notch, and Wnt, which orchestrate the transcriptional programs necessary for endothelial fate.
Differentiation into Endothelial Cells
In simple terms: The progenitor cells mature into endothelial cells, the building blocks of blood vessels.
Angioblasts undergo differentiation into endothelial cells, a process marked by the expression of endothelial-specific genes such as CDH5 (VE-cadherin), PECAM1 (CD31), and VWF. This differentiation is driven by transcription factors including ETV2, which is considered a master regulator of endothelial specification. The acquisition of endothelial identity involves changes in cell adhesion, cytoskeletal organization, and metabolic profile. In vitro models using embryonic stem cells or induced pluripotent stem cells have been used to recapitulate this step, revealing the importance of VEGF-A and its receptor VEGFR2 in promoting endothelial differentiation.
Migration and Assembly into Cord-like Structures
In simple terms: The new endothelial cells move and link up to form solid cords, the precursors of tubes.
Differentiated endothelial cells migrate and coalesce to form cord-like structures, which are the earliest morphological signs of vasculogenesis. This assembly is mediated by cell-cell adhesion molecules, including VE-cadherin and N-cadherin, and by interactions with the extracellular matrix. The cords then undergo reorganization to form a primitive vascular plexus, a network of interconnected tubes. This step is highly dependent on chemotactic cues, such as VEGF gradients, and on the activity of matrix metalloproteinases that remodel the surrounding matrix.
Lumen Formation and Tube Morphogenesis
In simple terms: The solid cords hollow out to become tubes that can carry blood.
Lumen formation is a critical step in vasculogenesis, converting solid endothelial cords into hollow tubes. This process involves the polarization of endothelial cells, the establishment of apical-basal polarity, and the fusion of intracellular vacuoles to create a continuous lumen. Key molecules include the Rho GTPases, PAR polarity complex, and CD34 sialomucin. In some contexts, lumen formation occurs through the rearrangement of endothelial cells into a cord that then cavitates, while in others it involves the coalescence of vacuoles. The resulting tubes connect to form a functional vascular network capable of supporting blood flow.
Postnatal Vasculogenesis
In simple terms: Even after birth, the body can grow new blood vessels from progenitor cells.
Although initially thought to be restricted to embryogenesis, vasculogenesis also occurs postnatally, contributing to neovascularization in tumors, ischemic tissues, and inflammatory diseases. Postnatal vasculogenesis involves the recruitment of endothelial progenitor cells (EPCs) from the bone marrow or peripheral blood to sites of neovascularization. These EPCs can incorporate into growing vessels and secrete pro-angiogenic factors. This phenomenon has been observed in infantile hemangioma, where vasculogenesis-like mechanisms drive tumor growth. The discovery of postnatal vasculogenesis has expanded the therapeutic potential of EPCs for regenerative medicine.
Key Genes Involved in GO:0001570 vasculogenesis
The following genes and proteins are central to the regulation and execution of vasculogenesis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFA | Key ligand that promotes endothelial differentiation and survival | Target for modulating vasculogenesis in development and disease |
| KDR (VEGFR2) | Receptor tyrosine kinase mediating VEGF signaling | Essential for hemangioblast and endothelial cell specification |
| ETV2 | Master transcription factor for endothelial lineage commitment | Critical for initiating vasculogenesis program |
| CDH5 (VE-cadherin) | Endothelial-specific adhesion molecule | Required for cord assembly and lumen formation |
| PECAM1 (CD31) | Adhesion molecule and endothelial marker | Used to identify endothelial cells during vasculogenesis |
| TEK (TIE2) | Receptor tyrosine kinase for angiopoietins | Regulates vessel stabilization and remodeling |
| TAL1 | Transcription factor in hemangioblast development | Involved in hematopoietic and endothelial lineage divergence |
| FLT1 (VEGFR1) | Modulates VEGF signaling | Regulates the balance between vasculogenesis and angiogenesis |
| NOTCH1 | Signaling receptor controlling cell fate decisions | Regulates endothelial tip/stalk cell selection |
| WNT5A | Non-canonical Wnt ligand | Promotes endothelial migration and tube formation |
| SOX17 | Transcription factor for endothelial specification | Required for arterial and venous differentiation |
| CD34 | Sialomucin involved in lumen formation | Marker of endothelial progenitors and regulator of tube morphogenesis |
| MMP2 | Matrix metalloproteinase | Facilitates extracellular matrix remodeling during vasculogenesis |
| MMP9 | Matrix metalloproteinase | Contributes to vascular basement membrane degradation |
| HIF1A | Hypoxia-inducible factor | Drives VEGF expression under hypoxic conditions |
| CXCR4 | Chemokine receptor for SDF-1 | Mediates endothelial progenitor cell recruitment |
| ITGB1 | Integrin beta 1 | Mediates cell-matrix adhesion during vascular assembly |
How Is vasculogenesis Regulated?
Vasculogenesis is tightly regulated by a network of signaling pathways and transcription factors. VEGF-A signaling through VEGFR2 (KDR) is the primary driver of endothelial differentiation and proliferation, and its expression is regulated by hypoxia via HIF1A. The Notch pathway modulates endothelial cell fate decisions, particularly during tip and stalk cell selection in sprouting vessels. Wnt signaling, including both canonical and non-canonical branches, influences endothelial specification and migration. Additionally, the transcription factor ETV2 acts as a master regulator of the endothelial program, and its expression is controlled by upstream signals such as BMP and FGF. Post-translational modifications, including phosphorylation and ubiquitination, further fine-tune the activity of key effectors. In pathological settings, such as clear cell renal cell carcinoma, dysregulated HIF1A and VEGF signaling can reactivate vasculogenesis to support tumor growth.
vasculogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VEGFA | Clear cell renal cell carcinoma, tumor angiogenesis | Knockout or overexpression in ccRCC cell lines |
| KDR (VEGFR2) | Infantile hemangioma, vascular anomalies | Point mutation to disrupt ligand binding in endothelial cells |
| ETV2 | Cardiovascular malformations | Knockout in induced pluripotent stem cells followed by endothelial differentiation |
| HIF1A | ccRCC, hypoxia-driven vasculogenesis | Knock-in of degradation-resistant HIF1A in renal cells |
| CXCR4 | Ischemic tissue repair, EPC recruitment | Overexpression in endothelial progenitor cells for cell therapy |
Vasculogenesis in Cancer
Vasculogenesis contributes to tumor vascularization in several malignancies, including clear cell renal cell carcinoma (ccRCC). In ccRCC, hypoxia-inducible factors drive the expression of VEGF and other pro-angiogenic factors, promoting the recruitment of endothelial progenitor cells and the formation of new blood vessels. This process supports tumor growth and metastasis and is associated with resistance to anti-angiogenic therapies. Targeting vasculogenesis in cancer may therefore offer a complementary strategy to conventional angiogenesis inhibitors.
Vasculogenesis in Infantile Hemangioma
Infantile hemangioma is a common benign vascular tumor of infancy that exhibits features of both vasculogenesis and angiogenesis. Studies have shown that hemangioma-derived endothelial cells express markers of progenitor cells and can form vessels de novo, suggesting a role for vasculogenesis in tumor initiation. The presence of endothelial progenitor cells in hemangioma tissue further supports this mechanism. Understanding vasculogenesis in this context may lead to new therapeutic approaches for hemangioma and other vascular anomalies.
Vasculogenesis in Cardiovascular Disease and Regeneration
Vasculogenesis is essential for embryonic heart development, and defects in this process can lead to congenital cardiovascular malformations. In adults, postnatal vasculogenesis mediated by endothelial progenitor cells contributes to tissue repair after ischemia, but its dysfunction is implicated in cardiovascular disease progression. Cell therapy using EPCs to promote vasculogenesis is being explored for ischemic heart disease and peripheral artery disease. However, the efficacy of such therapies depends on a better understanding of the molecular regulation of vasculogenesis.
From vasculogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ETV2 abolish endothelial differentiation? | ETV2 knockout in human iPSCs followed by vasculogenesis assay |
| Does a specific VEGFA point mutation impair VEGFR2 binding? | Knock-in of mutant VEGFA in endothelial cells |
| Can VE-cadherin tagging reveal lumen formation dynamics? | Knock-in of fluorescent tag at CDH5 locus |
| Does overexpression of HIF1A enhance vasculogenesis in ccRCC? | HIF1A overexpression in renal carcinoma cells |
| Is CXCR4 required for EPC recruitment to ischemic tissue? | CXCR4 knockout in endothelial progenitor cells |
| Can CRISPR library screening identify novel regulators of vasculogenesis? | Genome-wide knockout library in iPSC-derived endothelial cells |
How to Study the vasculogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| iPSC/ESC differentiation | Endothelial marker expression and tube formation | Modeling developmental vasculogenesis |
| 3D bioprinting | De novo vessel formation in engineered tissues | Tumor vasculogenesis modeling |
| Lineage tracing | Progenitor cell fate and migration | Embryonic vasculogenesis in zebrafish/mouse |
| CRISPR knockout screening | Gene essentiality for endothelial differentiation | Discovery of novel vasculogenesis regulators |
| Single-cell RNA-seq | Transcriptional heterogeneity during differentiation | Identifying endothelial subpopulations |
| Immunofluorescence | Protein localization and tube morphology | Visualizing lumen formation |
| Flow cytometry | Quantification of endothelial progenitors | Assessing differentiation efficiency |
| Matrigel tube formation assay | In vitro capillary-like network formation | Functional assessment of endothelial cells |
In Vitro Differentiation Assays
In vitro models using embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) are widely used to study vasculogenesis. These cells can be differentiated into endothelial cells through the formation of embryoid bodies or monolayer cultures, and the emergence of endothelial markers such as CD31 and VE-cadherin can be monitored by flow cytometry and immunofluorescence. These assays allow researchers to dissect the stepwise differentiation of progenitors into endothelial cells and to test the effects of genetic perturbations.
Three-Dimensional Bioprinting and Tissue Engineering
Recent advances in 3D bioprinting have enabled the creation of vascularized tissue constructs that mimic vasculogenesis. By co-printing endothelial progenitors with supporting cells and extracellular matrix, researchers can observe de novo vessel formation in a controlled microenvironment. This technology is particularly useful for modeling tumor vasculogenesis and for engineering vascularized tissues for regenerative medicine.
Genetic Lineage Tracing and Imaging
Lineage tracing using Cre-lox or fluorescent reporters in animal models allows visualization of endothelial progenitor cells as they differentiate and assemble into vessels. Zebrafish and mouse embryos are common models for live imaging of vasculogenesis, leveraging fluorescently tagged endothelial markers. These techniques provide spatiotemporal insights into cell migration, cord formation, and lumenization.
Molecular Profiling and CRISPR Screening
Transcriptomic and proteomic profiling of endothelial progenitors during vasculogenesis can identify novel regulators and signaling pathways. CRISPR-based loss-of-function screens in iPSC-derived endothelial cells have been used to systematically discover genes required for endothelial differentiation and tube formation. Such screens can be combined with single-cell RNA sequencing to resolve heterogeneity within differentiating populations.
How CRISPR Can Be Used to Study GO:0001570 vasculogenesis
Knockout
CRISPR knockout is used to ablate genes suspected to be essential for vasculogenesis, such as ETV2, KDR, or CDH5. By generating knockout iPSC lines or endothelial cells, researchers can assess the requirement for these genes in endothelial differentiation, cord formation, and lumenization. Knockout models also help validate findings from genome-wide screens and can reveal compensatory mechanisms.
Point Mutation
Point mutations can be introduced to model specific amino acid changes that affect protein function, such as disrupting the kinase activity of VEGFR2 or the binding interface of VE-cadherin. These models are valuable for understanding structure-function relationships and for mimicking human disease variants associated with vascular anomalies.
Knock-in
Knock-in strategies enable the insertion of reporter tags (e.g., GFP, luciferase) or epitope tags into endogenous loci, such as CDH5 or PECAM1, to track endothelial cells during vasculogenesis. This approach allows real-time monitoring of progenitor differentiation and vessel assembly in vitro and in vivo. Knock-in can also be used to express mutant proteins under endogenous regulatory control.
Overexpression
Overexpression of pro-vasculogenic factors, such as VEGFA or HIF1A, can be achieved by CRISPR-mediated insertion of a strong promoter or by lentiviral delivery. Overexpression models are useful for studying gain-of-function effects, such as enhanced endothelial differentiation or tumor vascularization, and for testing therapeutic hypotheses.
How EDITGENE Supports vasculogenesis Research
Researchers studying vasculogenesis-related genes often need to determine whether a candidate gene is causally involved in endothelial differentiation, tube formation, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation and mechanistic studies in the context of GO:0001570.
Contact EDITGENE today to design your custom CRISPR model for vasculogenesis research.
Frequently Asked Questions About vasculogenesis
What is vasculogenesis GO:0001570?
Vasculogenesis (GO:0001570) is the biological process in which endothelial cells differentiate from progenitor cells and form new blood vessels and tubes de novo, as defined by the Gene Ontology.
What is the difference between vasculogenesis and angiogenesis?
Vasculogenesis is the de novo formation of blood vessels from endothelial progenitors, while angiogenesis is the formation of new vessels from pre-existing ones.
What genes are involved in vasculogenesis?
Key genes include VEGFA, KDR (VEGFR2), ETV2, CDH5 (VE-cadherin), PECAM1, TEK (TIE2), and TAL1, among others.
Where does vasculogenesis occur?
Vasculogenesis primarily occurs during embryonic development but can also occur postnatally in tumors, ischemic tissues, and inflammatory conditions.
What are hemangioblasts and angioblasts?
Hemangioblasts are bipotent progenitors that give rise to both blood and endothelial cells, while angioblasts are committed endothelial progenitors that differentiate into endothelial cells.
How is vasculogenesis studied in the lab?
Common methods include iPSC/ESC differentiation assays, 3D bioprinting, lineage tracing in animal models, and CRISPR screening.
What diseases involve abnormal vasculogenesis?
Diseases include clear cell renal cell carcinoma, infantile hemangioma, and cardiovascular malformations.
Can CRISPR be used to study vasculogenesis?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in vasculogenesis.
What is the role of VEGF in vasculogenesis?
VEGFA signaling through VEGFR2 (KDR) is a primary driver of endothelial differentiation, proliferation, and survival during vasculogenesis.
What is postnatal vasculogenesis?
Postnatal vasculogenesis is the formation of new blood vessels from endothelial progenitor cells after birth, contributing to tissue repair and tumor growth.
Conclusion
Vasculogenesis (GO:0001570) is a fundamental biological process that establishes the vascular system during development and contributes to postnatal neovascularization in health and disease. Its molecular regulation involves a complex interplay of growth factors, receptors, and transcription factors, many of which have been validated through CRISPR-based studies. Understanding vasculogenesis not only sheds light on embryonic development but also offers therapeutic opportunities for cancer, cardiovascular disease, and regenerative medicine. EDITGENE's suite of CRISPR services empowers researchers to interrogate the genes and pathways controlling vasculogenesis with precision and reproducibility.
References
- 1. Ribatti D et al.. 2001. Postnatal vasculogenesis.. Mech Dev 100(2):157-63 PMID: 11165474
- 2. Borasch K et al.. 2020. Cardiogenesis with a focus on vasculogenesis and angiogenesis.. Anat Histol Embryol 49(5):643-655 PMID: 32319704
- 3. Shukla AK et al.. 2024. Advancement in Cancer Vasculogenesis Modeling through 3D Bioprinting Technology.. Biomimetics (Basel) 9(5) PMID: 38786516
- 4. Ratajska A et al.. 2017. Vasculogenesis and Its Cellular Therapeutic Applications.. Cells Tissues Organs 203(3):141-152 PMID: 27654624
- 5. Boscolo E et al.. 2009. Vasculogenesis in infantile hemangioma.. Angiogenesis 12(2):197-207 PMID: 19430954
- 6. Eichmann A et al.. 2002. Vasculogenesis and the search for the hemangioblast.. J Hematother Stem Cell Res 11(2):207-14 PMID: 11983094
- 7. Cosma AA et al.. 2024. Exploring vasculogenesis in the normal human kidney and clear cell renal cell carcinoma: insights from development to tumor progression and biomarkers for therapy response.. Front Oncol 14:1375190 PMID: 38746686
- 8. Patan S. 2004. Vasculogenesis and angiogenesis.. Cancer Treat Res 117:3-32 PMID: 15015550
